We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,650

Confidentiality in BPCIA Cases
  • Fish & Richardson PC
  • USA
  • January 5 2017

The Biologics Price Competition and Innovation Act ("BPCIA") contemplates the exchange of highly sensitive information from the pre-suit "patent


U.S. International Trade Commission To Review ALJ’s Dismissal Of Antitrust-Based Claims In Carbon And Alloy Steel Products
  • Squire Patton Boggs
  • USA
  • December 20 2016

The USITC’s investigation in Certain Carbon and Alloy Steel Products, Inv. No. 337-TA-1002 was instituted to investigate alleged violations of


The vexed question of the appropriate ‘royalty base’ for FRAND-based damages - the US Supreme Court declines to answer
  • Bristows LLP
  • United Kingdom, USA
  • December 15 2016

Apple and Samsung have been engaged in litigation in the USA since 2011 over the issue of whether various Samsung smartphones infringed a number of


ALJ Lord Dismisses Antitrust-Based Claims In Carbon And Alloy Steel Products Investigation
  • Squire Patton Boggs
  • USA
  • November 21 2016

In May, the ITC instituted its investigation of Certain Carbon and Alloy Steel Products, Inv. No. 337-TA-1002, based on alleged violations of Section


Supreme Court Denies Cert in Lamictal Pay-For-Delay Litigation
  • Latham & Watkins LLP
  • USA
  • November 15 2016

On November 7, 2016, the Supreme Court of the United States declined to hear the petition of GlaxoSmithKline LLC (GSK), Teva Pharmaceutical Industries


Massachusetts Court Weighs in on Product Hopping Allegations and Reverse Payment Standing
  • McDermott Will & Emery
  • USA
  • November 11 2016

Addressing a motion to dismiss a bevy of antitrust allegations, the US District Court for the District of Massachusetts held that a class of


Northern District of California Dismisses Claims that Gilead Violated the Antitrust Laws in Seeking to Protect its Position on HIV Drug
  • McDermott Will & Emery
  • USA
  • November 11 2016

Ruling on a motion to dismiss, the US District Court for the Northern District of California dismissed AIDS Healthcare's antitrust claims alleging


Second Circuit: No Valid Sherman Act Claim Where Citizen Petition Denied Contemporaneously with ANDA Approval
  • McDermott Will & Emery
  • USA
  • November 11 2016

The US Court of Appeals for the Second Circuit held that a pharmaceutical manufacturer failed to state a Sherman Act Section Two claim because the


Two reverse-payment appeals to watch
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • November 10 2016

It has been over three years since the Supreme Court’s Actavis decision. Since then, numerous putative class actions alleging harm to competition as a


FTC Issues Study On Patent Assertion Entity Activity -Why Was It Silent on Competition And Can We Expect Enforcement Action?
  • Squire Patton Boggs
  • USA
  • November 2 2016

Patent assertion entities (PAEs), firms that purchase pre-existing patents and then license them for products that are already on the market, have